Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06381869
Other study ID # CRNHA 2018-2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 10, 2019
Est. completion date June 13, 2019

Study information

Verified date April 2024
Source Roquette Freres
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study done in healthy, non-malnourished young and elderly subjects, is to measure the bioavailability of protein intake and the variation of metabolic markers following consumption of pea protein " NUTRALYS ® S85 plus" or a reference protein brought in water either alone or at the end of a standardized meal.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 13, 2019
Est. primary completion date June 13, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Adult male volunteers, aged over 65 or under 30 - Body mass index (weight in kg/ height² in m²) between 22 and 28 kg/m², - Subjects considered to be healthy by the principal investigator doctor according to the interview, medical and clinical examination, - Biological assessment considered compatible with participation in the study, - Persons able to sign the informed consent, - Persons affiliated to social security scheme. Exclusion Criteria: - Pathologies or treatments not compatible with the study - Food allergy or a contraindication to the consumption of the products tested - Subject in a situation which, in the opinion of the investigator, could interfere with their optimal participation in the study or constitute a particular risk for the subject, - Subject with a particular diet (vegetarians, vegans, nutritional supplements, etc.), - Subject weighing < 55 kg,

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Pea protein (NUTRALYS ® S85 plus) in water
After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.
Pea protein (NUTRALYS ® S85 plus) within meal
After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.
Whey protein in water
After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.
Whey protein within meal
After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.

Locations

Country Name City State
France Unité d'Exploration en Nutrition Centre de Recherche en Nutrition Humaine d'Auvergne Clermont-Ferrand

Sponsors (3)

Lead Sponsor Collaborator
Roquette Freres CRNH Auvergne, Université d'Auvergne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Leucine blood concentration 0 minute before eating the test meals, then regularly until 360 minutes after ingestion.
Secondary Essential amino acids blood concentration (µmol/L) 0 minute before eating the test meals, then regularly until 360 minutes after ingestion.
Secondary Non essential amino acid blood concentration (µmol/L) 0 minute before eating the test meals, then regularly until 360 minutes after ingestion.
Secondary Blood glucose concentration (g/L) 0 minute before eating the test meals, then regularly until 360 minutes after ingestion.
Secondary Blood insulin concentration (µIU/ml) 0 minute before eating the test meals, then regularly until 360 minutes after ingestion.
Secondary Blood lipid profile (glycerol concentration in mg/l and non-esterified fatty acids concentration in mg/l) 0 minute before eating the test meals, then regularly until 360 minutes after ingestion.
Secondary Blood inflammatory profile (TNF-a blood concentration in pg/ml and IL-6 blood concentration in pg/ml) 0 minute before eating the test meals, then regularly until 360 minutes after ingestion.
See also
  Status Clinical Trial Phase
Completed NCT05523687 - AME Study of [14C]-PC14586 in Healthy Male Participants Phase 1
Completed NCT02250976 - The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Phase 1
Completed NCT01948011 - Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules Phase 1
Completed NCT04086719 - An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. Phase 1
Completed NCT03686501 - D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 Early Phase 1
Terminated NCT01965301 - First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 Phase 1
Completed NCT01005160 - Drug Interaction Between CKD-501 and Metformin Phase 1
Completed NCT04534582 - Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects Phase 1
Recruiting NCT06159101 - A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects Phase 1
Completed NCT01549743 - The Pharmacokinetic Interaction Between Celecoxib and Rebamipide Phase 1
Completed NCT03532854 - Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802 Phase 1
Recruiting NCT03530228 - A Phase 1 Study of Tegoprazan on Healthy Male Volunteers Phase 1
Completed NCT01356043 - CKD-828 Drug Interaction Study (S-amlodipine) Phase 1
Completed NCT04810533 - The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers Phase 1
Completed NCT03089112 - Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501 Phase 1
Completed NCT01939639 - The Influence of Oxytocin on the Processing of Social Contact Phase 1
Completed NCT01342055 - Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers Phase 1
Terminated NCT03863587 - Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects Phase 1
Completed NCT01356017 - CKD-828 Drug Interaction Study (Telmisartan) Phase 1
Completed NCT01382017 - Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study N/A